Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer.

Bremmer, Felix; Jarry, Hubertus; Unterkircher, Valerie; Kaulfuss, Silke; Burfeind, Peter; Radzun, Heinz-Joachim; Ströbel, Philipp; Thelen, Paul

Bremmer, Felix; Jarry, Hubertus; Unterkircher, Valerie; Kaulfuss, Silke; Burfeind, Peter; Radzun, Heinz-Joachim; Ströbel, Philipp; Thelen, Paul.

Afiliação

Bremmer F; Institute of Pathology, University Medical Center, Göttingen 37075, Germany.
Jarry H; Department of Experimental Endocrinology, University Medical Center, Göttingen 37075, Germany.
Unterkircher V; Institute of Pathology, University Medical Center, Göttingen 37075, Germany.
Kaulfuss S; Institute of Human Genetics, University Medical Center, Göttingen 37073, Germany.
Burfeind P; Institute of Human Genetics, University Medical Center, Göttingen 37073, Germany.
Radzun HJ; Institute of Pathology, University Medical Center, Göttingen 37075, Germany.
Ströbel P; Institute of Pathology, University Medical Center, Göttingen 37075, Germany.
Thelen P; Department of Urology, University Medical Center, Göttingen 37075, Germany.

Oncotarget ; 9(24): 16951-16961, 2018 Mar 30.

Article em En | MEDLINE | ID: mdl-29682196

Palavras-chave

3a-androstendiol; 3b-androstendiol; AKR1C1; AKR1C2 and AKR1C3; castration resistant prostate cancer

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google